Phytotherapy Research (PHYTOTHER RES )
Phytotherapy Research is a bimonthly plus two additional issues international journal for the publication of original medical plant research including biochemistry and molecular pharmacology toxicology pathology and the clinical applications of herbs and natural products to both human and animal medicine. Papers are also published concerning chemical and botanical identification of herbs or their products where such information contributes to the overall safety of plant based medicines currently in use. Papers and communications concerned solely with the identification and structure elucidation of natural products will only be considered where the work contributes directly to the understanding of the use of the plant as a medicine. Phytotherapy Research publishes full-length original research papers short communications reviews and letters on medicinal plant research. Clincal papers on the applications of herbs and natural products to both human and animal medicine may vary from case histories to full clinical trials. Papers concerned with the effects of common food ingredients and standardised plant extracts including commercial products are welcome as are mechanistic studies on isolated natural products. Phytotherapy Research does not publish purely agricultural phytochemical structure elucidation and identification papers unless pertinent to the pharmacological effects or overall safety of plant based medicines currently in use. Papers dealing with the pharmacology and screening of crude extracts often deal with local medicinal plants and are of only limited interest to an international readership. Therefore please consider carefully whether your paper would be more appropriate to a national journal before sending it to Phytotherapy Research . Crude extract papers will still be considered for publication as short communications but only if they are a single published page in length (equivalent to 600 words to include due allowance for any illustrations). Longer manuscripts will be returned without being reviewed .
- Impact factor2.40Show impact factor historyHide impact factor history
- 5-year impact2.44
- Cited half-life6.60
- Immediacy index0.44
- Article influence0.49
- WebsitePhytotherapy Research website
- Other titlesPhytotherapy research (Online), Phytotherapy research, PTR
- Material typeDocument, Periodical, Internet resource
- Document typeInternet Resource, Computer File, Journal / Magazine / Newspaper
- Author can archive a pre-print version
- Author can archive a post-print version
- See Wiley-Blackwell entry for articles after February 2007
- On personal web site or secure external website at authors institution
- Deposit in institutional repositories is not allowed
- JASIST authors may deposit in an institutional repository
- Pre-print must be accompanied with set phrase (see individual journal copyright transfer agreements)
- Published source must be acknowledged with set phrase (see individual journal copyright transfer agreements)
- Publisher's version/PDF cannot be used
- Articles in some journals can be made Open Access on payment of additional charge
- 'John Wiley and Sons' is an imprint of 'Wiley'
- Classification green
Publications in this journal
- Phytotherapy Research 12/2014;
- [Show abstract] [Hide abstract]
ABSTRACT: Euphorbia kansui (EK) has been widely used in traditional Chinese medicine (TCM); however, it possesses toxic effects. The fruits of Zizyphus jujuba (ZJ) are frequently co‐used with EK to reduce EK's toxicity. The present study is to clarify the toxicity of water extract of EK and explore the detox effect of ZJ using 1H NMR‐based metabonomic approach. The water extracts of ZJ, EK and the co‐use of EK and ZJ (CEZ) were orally administered to SD rats at designed doses for 1 week, respectively, and one more week observation was further conducted. Histopathological studies of liver samples from all groups showed no negative impacts. In metabonomic analyses of urines, ZJ showed no toxicity, while significant changes of metabolites indicating liver damages, kidney lesions and imbalance of gut microbes were clearly observed during the second week in EK‐treated rats. Very meaningfully, CEZ clearly indicated that the toxicities appeared at the first week and became weaker, and furthermore, was recovered during the second week. These results clearly demonstrated the rationality of traditional co‐use of EK together with ZJ, and the metabonomic approach should be a promising tool to research the toxicity of TCM. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 11/2013; 27(11).
Article: Anti‐Angiogenic Activity of[Show abstract] [Hide abstract]
ABSTRACT: Herba Epimedii, an herb commonly used in East Asian medicine, is commonly used for treatment of impotence, osteoporosis and many inflammatory conditions in traditional Chinese medicine. Recent studies revealed that Herba Epimedii also has anti‐tumor or anti‐cancer activities, which may possibly be mediated through anti‐angiogenesis. This study aims to examine and confirm the anti‐angiogenic activity in the herb using both in vivo and in vitro approaches. The 95% ethanol extract and four subsequent fractions (n‐hexane, ethyl acetate (EA), n‐butanol and aqueous fractions) of Herba Epimedii were tested on the zebrafish model by the quantitative assay for endogenous alkaline phosphatase; then, the active fraction was further tested on Tg(fli1a:EGFP)y1 zebrafish embryos and human umbilical vein endothelial cells (HUVECs) for the anti‐angiogenic effects. In addition, the action mechanism of Herba Epimedii was further investigated on wild‐type zebrafish embryos and HUVECs. The EA fraction showed anti‐angiogenic effects in both in vivo and in vitro models. Further experiments demonstrated that it might affect angiogenesis by acting on multiple molecular targets in zebrafish embryos and ERK signaling pathway in HUVECs. In conclusion, Herba Epimedii can inhibit angiogenesis, which may be the mechanism for its anti‐inflammatory, anti‐tumor and anti‐cancer actions. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 09/2013; 27(9).
Article: Lupenone Isolated from[Show abstract] [Hide abstract]
ABSTRACT: Adenophora triphylla var. japonica (Campanulaceae) is known to have anti‐inflammatory and anti‐tussive effects. Dysfunction of adipocytes and adipose tissue in obesity is related to various inflammatory cytokines or adipokines. In this study, we investigated whether lupenone isolated from A. triphylla var. japonica extract inhibits adipocyte differentiation and expression of adipogenic marker genes in 3T3‐L1 preadipocytes. We demonstrated that lupenone resulted in a significant reduction in lipid accumulation and expression of adipogenic marker genes in a dose‐dependent manner. In addition, lupenone decreased the transcriptional activity of peroxisome proliferator‐activated receptor γ (PPARγ) induced by troglitazone, and we also demonstrated that lupenone suppressed the PPARγ and CCAAT‐enhancer‐binding protein α (C/EBPα) protein levels. These findings demonstrated that lupenone isolated from A. triphylla var. japonica extract effectively inhibited adipocyte differentiation through downregulation of related transcription factor, particularly the PPARγ gene. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(5).
- [Show abstract] [Hide abstract]
ABSTRACT: Houttuynia cordata Thunb. (HC) is a medicinal herb that generally used in traditional Chinese medicine for treating allergic inflammation. The present study investigated the inhibitory effect of the volatile oil from HC Thunb. on animal models of inflammation and the production of inflammatory mediators in vivo and in vitro. In vivo, xylene‐induced mouse ear edema, formaldehyde‐induced paw edema and carrageenan‐induced mice paw edema were significantly decreased by HC volatile oil. HC volatile oil showed pronounced inhibition of prostaglandin (PG) E2 and malondialdehyde production in the edematous exudates. In vitro exposure of mouse resident peritoneal macrophages to 1, 10, 100 and 1000 µg/mL of HC volatile oil significantly suppressed lipopolysaccharide (LPS)‐stimulated production of NO and tumor necrosis factor‐α (TNF‐α) in a dose‐dependent manner. Exposure to HC volatile oil had no effect on cell viability and systemic toxicity. Furthermore, HC volatile oil inhibited the production of NO and TNF‐α by down‐regulating LPS‐stimulated iNOS and TNF‐α mRNA expression. Western blot analysis showed that HC volatile oil attenuated LPS‐stimulated synthesis of iNOS and TNF‐α protein in the macrophages, in parallel. These findings add a novel aspect to the biological profile of HC and clarify its anti‐inflammatory mechanism. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(11).
- [Show abstract] [Hide abstract]
ABSTRACT: Allergic asthma is associated with Th2‐mediated inflammation. Several flavonoids were isolated from Glycyrrhiza uralensis, one of the herbs in the anti‐asthma herbal medicine intervention. The aim of this investigation was to determine whether Glycyrrhiza uralensis flavonoids have inhibitory effects on memory Th2 responses in vitro and antigen‐induced Th2 inflammation in vivo. The effects of three Glycyrrhiza uralensis flavonoids on effector memory Th2 cells, D10.G4.1 (D10 cells), were determined by measuring Th2 cytokine production. Isoliquiritigenin, 7, 4′‐dihydroxyflavone (7, 4′‐DHF) and liquiritigenin significantly suppressed IL‐4 and IL‐5 production in a dose‐dependent manner, 7, 4′‐DHF being most potent. It was also evaluated for effects on D10 cell proliferation, GATA‐3 expression and IL‐4 mRNA expression, which were suppressed, with no loss of cell viability. Chronic treatment with 7, 4′‐DHF in a murine model of allergic asthma not only significantly reduced eosinophilic pulmonary inflammation, serum IgE levels, IL‐4 and IL‐13 levels, but also increased IFN‐γ production in lung cell cultures in response to antigen stimulation. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(9).
- [Show abstract] [Hide abstract]
ABSTRACT: This study investigated the glucose uptake activity of the water extracts from the leaves and fruit of edible Myrtaceae plants, including guava (Psidium guajava Linn.), wax apples [Syzygium samarangense (Blume) Merr. and L.M. Perry], Pu‐Tau [Syzygium jambo (L.) Alston], and Kan‐Shi Pu‐Tau (Syzygium cumini Linn.) in FL83B mouse hepatocytes. The fluorescent dye 2‐(n‐(7‐nitrobenz‐2‐oxa‐1,3‐diazol‐4‐yl)amino)‐2‐deoxyglucose was used to estimate the uptake ability of the cells. Glucose uptake test showed that pink wax apple fruit extract (PWFE) exhibits the highest glucose uptake activity, at an increment of 21% in the insulin‐resistant FL83B mouse hepatocytes as compared with the TNF‐α‐treated control group. Vescalagin was isolated using column chromatography of PWFE. This compound, at the concentration of 6.25 µg/mL, exhibits the same glucose uptake improvement in insulin‐resistant cells as PWFE at a 100‐µg/mL dose. We postulate that vescalagin is an active component in PWFE that may alleviate the insulin resistance in mouse hepatocytes. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(2).
- [Show abstract] [Hide abstract]
ABSTRACT: We investigated the toxicity, psychotropic side effects and anxiolytic potential of an Echinacea angustifolia extract that produced promising effects in laboratory tests performed earlier. Rats were studied in the elevated plus‐maze, conditioned fear, open‐field, object recognition and conditioned place preference tests. Toxicity was studied in rats after intragastric administration. The preparation decreased anxiety in the elevated plus‐maze and ameliorated contextual conditioned fear. No lethality or behavioural signs of discomfort were noticed in rats treated with 1000 and 3000 mg/kg Echinacea angustifolia. The extract was without effect in tests of locomotion (open‐field), memory (object recognition) and rewarding potential (conditioned place preference) within a wide dose range. A pharmacological formulation based on the same E. angustifolia extract was tested in human subjects. One or two tablets per day were administered for 1 week to healthy volunteers scoring high on the State‐Trait Anxiety Inventory (STAI). The tablets contained 20 mg of the plant extract. Data were collected using a structured self‐assessment diary technique. The high dose (2 tablets per day) decreased STAI scores within 3 days in human subjects, an effect that remained stable for the duration of the treatment (7 days) and for the 2 weeks that followed treatment. The lower dose (1 tablet per day) did not affect anxiety significantly. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(1).
Article: Investigation of the[Show abstract] [Hide abstract]
ABSTRACT: Evodiamine is the main active alkaloid of Evodia rutaecarpa (E. rutaecarpa) and has been demonstrated to exhibit many pharmacological activities including vasorelaxation, uterotonic action, anoxia and control of body temperature. The present study focused on the metabolism of evodiamine. Human and phenobarbital‐induced rat liver microsomal incubation of evodiamine in the presence of NADPH resulted in the formation of five major metabolites (M‐1, M‐2, M‐3, M‐4, M‐5). Four metabolites (M‐1, M‐2, M‐3 and M‐5) were identified to mono‐hydroxylated evodiamine and one metabolite (M‐4) was identified to be N‐demethylated evodiamine. CYP3A4, CYP2C9 and CYP1A2 were identified to be the main CYP isoforms involved in the metabolism of evodiamine in human liver microsomes. Finding new metabolites can help us decipher novel substance basis of efficiency and toxicity. Elucidation of drug metabolizing enzymes will facilitate explaining the individual difference for response to the same drugs or herbs and the potential drug–drug interaction or herb–drug interaction. Taken together, these results are of significance for better understanding the pharmacokinetic behaviour of evodiamine and helpful for clinical application of evodiamine and E. rutaecarpa. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(5).
Article: Extracts of[Show abstract] [Hide abstract]
ABSTRACT: Scutellaria baicalensis has been extensively employed for the clinical treatment of hyperlipidemia, atherosclerosis, hypertension, dysentery, inflammatory diseases, and the common cold. The present study was performed to investigate the anti‐obesity and anti‐dyslipidemia effect of Scutellaria baicalensis extracts (SBE) in type 2 diabetic db/db mice.Male db/db mice were divided into three groups (n = 5) and orally administrated vehicle (control), SBE 10, and 100 mg/kg body weight/day for 4 weeks everyday. Administration of SBE improves weight gain, hypertriglyceridemia, and hyperinsulinemia in db/db mice. In obese db/db mice, SBE treatment also reduced plasma alanine aminotransferase levels. In the livers of db/db mice, SBE promoted 5' AMP‐activated protein kinase activity and restored metabolic process and insulin signaling pathways. Our data demonstrate that SBE exerts potent anti‐obesity and anti‐hypertriglyceride effects suggesting its useful potential function as adjuvant therapeutic agent for the treatment of weight gain and hypertriglyceridemia. Copyright © 2012 John Wiley & Sons, Ltd.Phytotherapy Research 01/2013; 27(2).
- Phytotherapy Research 04/2012;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.